VYTORIN Drug Patent Profile

When do Vytorin patents expire, and what generic alternatives are available?

Vytorin is a drug marketed by Organon and is included in one NDA.

The generic ingredient in VYTORIN is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vytorin

A generic version of VYTORIN was approved as ezetimibe; simvastatin by DR REDDYS LABS SA on April 26^th, 2017.

Summary for VYTORIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	42
Patent Applications:	770
Drug Prices:	Drug price information for VYTORIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYTORIN
What excipients (inactive ingredients) are in VYTORIN?	VYTORIN excipients list
DailyMed Link:	VYTORIN at DailyMed

See drug prices for VYTORIN

See drug sales revenues for VYTORIN

Recent Clinical Trials for VYTORIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cedars-Sinai Medical Center	PHASE2
Samsung Medical Center	Phase 4
Aswan Heart Centre	N/A

See all VYTORIN clinical trials

Pharmacology for VYTORIN

Drug Class	Dietary Cholesterol Absorption Inhibitor HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors
Physiological Effect	Decreased Cholesterol Absorption

Paragraph IV (Patent) Challenges for VYTORIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYTORIN	Tablets	ezetimibe; simvastatin	10 mg/10 mg 10 mg/20 mg 10 mg/40 mg 10 mg/80 mg	021687	1	2009-07-27

US Patents and Regulatory Information for VYTORIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-001	Jul 23, 2004	AB	RX	Yes	No
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-004	Jul 23, 2004	AB	RX	Yes	Yes
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-002	Jul 23, 2004	AB	RX	Yes	No
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-003	Jul 23, 2004	AB	RX	Yes	No

Expired US Patents for VYTORIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-001	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-003	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-004	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-002	Jul 23, 2004

International Patents for VYTORIN

See the table below for patents covering VYTORIN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	16704
Australia	548996
Australia	6657381
Bulgaria	61418
Canada	1199322	COMPOSES ANTIHYPERCHOLESTEROLEMIQUES (ANTIHYPERCHOLESTEROLEMIC COMPOUNDS)
Czechoslovakia	233718	PROCESSING OF 2H-PYRAN-2 ACYLOXYPOLYHYDRONAPHTYLDERIVATIVE

Supplementary Protection Certificates for VYTORIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0033538	SPC/GB93/005	United Kingdom
0720599	300132	Netherlands		300132, 20140914, EXPIRES: 20171016
0720599	0390018-0	Sweden		PRODUCT NAME: EZETIMIB
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599	SPC/GB03/023	United Kingdom		PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
0720599	SZ 20/2003	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON

Last updated: July 22, 2026

Vytorin (Ezetimibe/Simvastatin) Market Dynamics and Financial Trajectory: Sales Trends, Exclusivity, Patent/Generic Risk, and Competitive Pressure

Vytorin (ezetimibe/simvastatin) has transitioned from a branded cholesterol therapy to a largely off-cycle, post–peak-sales product in the US and major markets. The commercial trajectory has been shaped by (1) outcome-based guideline friction after major cardiovascular outcomes trials, (2) payer and formulary shifts toward generic statins and alternative add-on lipid therapies, and (3) structural erosion from loss of branded pricing power and increased generic uptake. Patent and exclusivity have shifted the competitive set toward generic ezetimibe/simvastatin combinations and broad statin classes, which compress margin and limit brand-sponsored revenue growth.

---

How did Vytorin sales perform over time in the US and major markets?

US sales trajectory and peak-to-decline shape

Vytorin’s US branded sales show the classic trajectory of an “incremental” cardiometabolic add-on that faced hard outcomes evidence and then experienced ongoing price and volume pressure as competitors broadened. After early adoption post-launch, growth flattened and then declined as:

• clinicians reduced reliance on add-on ezetimibe/simvastatin versus high-intensity statin strategies,
• payers moved to tiering and prior authorization emphasizing less costly alternatives, and
• generics and therapeutic substitutes expanded market share.

Global dynamics track US erosion

Outside the US, the same forces applied through local formulary evolution:

• generic statins rapidly captured base-LDL volume,
• ezetimibe monotherapy uptake limited add-on combination demand, and
• combination use narrowed to specific tolerability or insufficient-response segments where clinicians still preferred fixed-dose simplicity.

---

What market forces drove Vytorin decline: outcomes evidence, guidelines, and payer controls?

Clinical outcomes friction and guideline steering

Vytorin’s market position depended on the incremental LDL lowering of ezetimibe added to statin. Its commercial durability weakened as guideline committees and payers increasingly aligned with outcome data and risk-based statin intensity:

• high-intensity statins became the preferred baseline for many patients,
• add-on therapy shifted toward agents with clearer outcomes differentiation or narrower use cases.

Formulary and benefit design

Commercial realities for branded combinations in cholesterol management:

• step therapy commonly favored generic statins first,
• ezetimibe monotherapy often priced lower than branded combination products,
• combination brands faced higher hurdles for coverage unless a patient already stabilized on the fixed dose.

Therapeutic substitution from broader lipid pipelines

Even without replacing ezetimibe specifically, the “cholesterol management” market broadened materially:

• PCSK9 inhibitors gained share in eligible high-risk populations,
• newer lipid-modifying agents expanded payer discussions around outcome-driven add-on therapy. This widened the competition set beyond statin/ezetimibe combinations.

---

When did Vytorin lose exclusivity, and what generic entry risk existed by dosage strength and route?

Orange Book and exclusivity exposure

The generic risk profile for Vytorin depends on:

• patent listings for the active ingredients’ combination product,
• formulation/compound patents,
• method-of-use claims (if any) and their litigation status,
• FDA exclusivity periods tied to particular NDA approvals or supplements (if applicable).

Practical generic entry mechanics

For a fixed-dose combination, generic entry typically accelerates when:

• composition-of-matter and key formulation patents expire or are successfully invalidated/settled,
• ANDA filers can avoid Paragraph IV barriers through design-around or authorization routes (where licensing exists),
• payers shift immediately after branded exclusivity lapses to least-cost options.

Impact on revenue: Even without a full “instant” collapse, branded revenue typically compresses within 6 to 24 months after generics establish volume share.

---

What patents protect Vytorin, and how did patent estate strength affect commercial sustainability?

Patent estate structure that typically matters for Vytorin-like combination products

For branded combination cholesterol drugs, the enforceable estate commonly spans:

• compound claims covering the combination or specific chemical forms,
• formulation claims for fixed-dose tablets,
• method-of-use claims tied to lipid-related indications,
• manufacturing process claims (less common as the primary revenue lever).

How patent strength translates into financial outcomes

A strong estate can delay generic volume capture, keeping branded unit share and list price intact. When the estate thins, branded revenue becomes a function of:

• residual patient retention,
• rebate sustainment,
• payer conversions to generics,
• competitive pricing behavior among generic manufacturers.

---

What Paragraph IV challenges or ANDA litigation affected Vytorin’s timeline?

Paragraph IV pathways

For combination statin/ezetimibe products, ANDA entrants generally use one of:

• Paragraph IV certifications to challenge patents listed in the Orange Book,
• design-around to avoid infringement of specific formulation/method claims,
• settlement agreements that convert litigation into a launch calendar.

Settlement calendars and delayed generic launches

A typical settlement structure affects the market in two steps:

1. the branded company receives a temporary restriction on generic launch (often with a calendar date),
2. after the restricted period ends, multiple ANDA products can launch rapidly, increasing competitive intensity and price compression.

---

What is the Orange Book status of Vytorin and its generic approvals?

How to read the Orange Book status for market planning

Orange Book listings determine:

• which patents can block generic entry,
• which patents are vulnerable to Paragraph IV litigation,
• whether the path is simply “date-based expiration” or “litigation/settlement-based launch.”

Generic approval signals

When generics receive FDA approval, the market often anticipates:

• formulary updates,
• rebate renegotiations,
• pricing resets and promotion changes by branded manufacturers.

---

How does Vytorin compare with simvastatin-only generics and other cholesterol therapies on market dynamics?

Statins as structural substitutes

Because statins dominate baseline LDL management, Vytorin competes against:

• generic high-volume simvastatin,
• other generic statins (atorvastatin, rosuvastatin),
• fixed-dose combinations of statins with other add-ons where available.

Market effect: Vytorin’s fixed-dose advantage is offset by the cost and coverage superiority of generic statins, plus the availability of ezetimibe as a monotherapy.

Ezetimibe monotherapy vs fixed-dose combination

Ezetimibe monotherapy often becomes the preferred “lower budget” add-on for patients needing more LDL lowering than statin alone.

Market effect: When payers require add-on therapy but reject branded fixed-dose pricing, the combination’s share declines and monotherapy captures the incremental segment.

PCSK9 inhibitors and other add-on classes

In high-risk populations, PCSK9 inhibitors and other outcomes-oriented therapies can dominate add-on decisions.

Market effect: As eligible populations shift to outcomes-driven add-on classes, combination ezetimibe/simvastatin use narrows.

---

What formulation and manufacturing/IP barriers exist for Vytorin generics?

Tablet formulation complexity

Generic entrants must match:

• active ingredient amounts,
• dissolution profile and bioequivalence,
• excipient choices that maintain stability and release.

Manufacturing readiness and competition

Once approved, generic competition accelerates price erosion:

• multiple manufacturers entering increases tendering advantage for wholesalers,
• pharmacy benefit managers consolidate contracting to the lowest net price.

Financial implication: Branded revenue declines typically become irreversible because the incremental value of “fixed-dose convenience” erodes under cost competition.

---

How did FDA regulatory decisions and labeling changes influence commercial trajectory?

Labeling and usage discipline

For cardiometabolic drugs, commercial value depends heavily on:

• indication breadth,
• label-specific appropriateness messaging,
• prescriber confidence in patient-selection.

If label evolution narrows use or increases reliance on clinician-guided risk stratification, overall addressable demand tightens.

Bioequivalence and generic labeling

Generic approvals also reduce brand differentiation because:

• substitution at the pharmacy level can occur without requiring prescriber reauthorization if state substitution rules apply and formularies favor generics.

---

Revenue exposure: what portion of the lipid market does Vytorin represent after exclusivity?

Post-erosion market share dynamics

After branded exclusivity and outcomes-guided prescribing shifts, the remaining demand for Vytorin tends to be:

• patient continuation where clinicians and patients already stabilized on the fixed dose,
• cost-sensitive patients where ezetimibe add-on is required but PCSK9 inhibitors are inaccessible,
• regional formularies that still cover combination therapy competitively.

Margin compression pathway

Financial trajectory post-erosion is typically:

• unit-share loss to generics and monotherapy,
• net price compression due to rebate pressure,
• spend reallocation away from brand growth toward compliance and lifecycle management.

---

Key takeaways for investors, licensors, and legal strategy

• Vytorin’s decline is structurally consistent with combination add-on therapies facing high-intensity statin preference, ezetimibe monotherapy substitution, and competitive add-on classes with strong payer pull.
• Revenue sustainability depends less on isolated unit retention and more on the timing of generic entry, breadth of patent coverage, and whether settlements delayed launches.
• Patent and Orange Book status determine the calendar for market share capture; once generics are entrenched, price compression becomes the dominant financial driver.
• For litigation and licensing planning in cholesterol combinations, the commercial objective is to control launch timing and limit multiple concurrent generic entrants.

---

FAQs

1) Why do add-on cholesterol combinations like Vytorin lose share after major outcomes trials?

Because prescribing shifts toward guideline-aligned statin-first strategies and add-ons with clearer payer-supported outcome differentiation.

2) Do Vytorin generics usually launch all strengths at once?

Generic launches often start with the most strategically positioned strengths and later expand as manufacturing lines and ANDA cohorts mature.

3) Does ezetimibe monotherapy typically outperform ezetimibe/simvastatin fixed-dose combinations after generic entry?

Often yes, because payers can cover ezetimibe monotherapy at lower net cost while still enabling individualized statin selection.

4) How do settlement agreements change the financial outlook for branded cholesterol drugs?

They can delay generic entry to a specific date, preserving branded unit share temporarily before competitive intensity accelerates.

5) What is the main driver of branded net price erosion for Vytorin after generic availability?

Rebate and formulary pressure tied to least-cost purchasing by PBMs and pharmacy chains.

---

Key Takeaways

Vytorin’s market dynamics are dominated by post-peak erosion from guideline steering, payer formulary design favoring generics and monotherapies, and competitive expansion in lipid add-on classes. Financial trajectory post-exclusivity is governed by Orange Book patent calendar and the number/timing of ANDA launches, which drive irreversible margin compression.

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA Drug Approval Reports and labeling databases for ezetimibe/simvastatin products. https://www.fda.gov/drugs/drug-approvals-and-databases

DrugChatter Q&A for VYTORIN

What are the benefits of Vytorin?